Unknown

Dataset Information

Novel mechanism-based therapeutics for androgen axis blockade in castration-resistant prostate cancer.


ABSTRACT:

Purpose of review

Understanding the mechanisms by which castration-resistant prostate cancer (CRPC) progresses provides an opportunity to identify novel therapeutic strategies to treat this disease. This understanding has led to approaches to attack prostate cancer's androgen axis in unique ways. This review will examine the classes of novel therapies for androgen axis blockade in CRPC, with a particular focus on the unique characteristics of drugs in various stages of clinical development.

Recent findings

The success of abiraterone and enzalutamide has stimulated multiple investigations into novel approaches to attack the androgen-signaling pathway. Drugs under development include cytochrome P17 inhibitors with 17,20-lyase specificity, androgen receptor antagonists that are

SUBMITTER: Teply BA 

PROVIDER: S-EPMC4896735 | biostudies-literature | 2016 Jun

REPOSITORIES: biostudies-literature